Patent foramen ovale (PFO) closure reduced the risk for recurrent ischemic stroke in most young and middle-aged adults with cryptogenic stroke but increased the risk for atrial fibrillation (AF) in a ...

Five-year results from the randomized REDUCE trial show a continued benefit of patent foramen ovale (PFO) closure compared with antiplatelet therapy alone for the prevention of cryptogenic stroke.

Patent foramen ovale (PFO) closure in conjunction with optimal medical therapy can reduce both the number of migraine days and the frequency of attacks compared with medicine alone, according to a new ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

The Society for Cardiovascular Angiography & Interventions (SCAI) today released official guidelines for the management of patent foramen ovale (PFO). A multidisciplinary guideline panel formulated 13 ...

Shown are Kaplan–Meier estimates in the intention-to-treat population. The inset shows the same data on an enlarged y axis. The incidence of serious adverse events was similar in the two trial groups, ...

W.L. Gore & Associates (Gore) has launched a multicenter, prospective, randomized placebo- and sham-controlled investigational study that will evaluate the safety and efficacy of transcatheter closure ...

CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ...

Please provide your email address to receive an email when new articles are posted on . A new classification system accurately predicted which patients with ischemic stroke of unknown original might ...

ATLANTA -- Scenarios for patent foramen ovale (PFO) closure not covered by the pivotal trials were a key subject of guidelines released by the Society for Cardiovascular Angiography and Interventions ...